US4162193A - Enzymatic cleavage of N-acyl-thienamycins - Google Patents

Enzymatic cleavage of N-acyl-thienamycins Download PDF

Info

Publication number
US4162193A
US4162193A US05/825,883 US82588377A US4162193A US 4162193 A US4162193 A US 4162193A US 82588377 A US82588377 A US 82588377A US 4162193 A US4162193 A US 4162193A
Authority
US
United States
Prior art keywords
thienamycin
acyl
process according
carbon atoms
acyl radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/825,883
Other languages
English (en)
Inventor
Jean S. Kahan
Frederick M. Kahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US05/825,883 priority Critical patent/US4162193A/en
Priority to PT68428A priority patent/PT68428A/pt
Priority to IT50747/78A priority patent/IT1106626B/it
Priority to EP78100699A priority patent/EP0000931B1/en
Priority to DE7878100699T priority patent/DE2861737D1/de
Priority to DK365478A priority patent/DK365478A/da
Priority to ES472701A priority patent/ES472701A1/es
Priority to IE1674/78A priority patent/IE47315B1/en
Priority to JP10046478A priority patent/JPS5446890A/ja
Application granted granted Critical
Publication of US4162193A publication Critical patent/US4162193A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20Sulfur atoms

Definitions

  • the enzyme, penicillin amidohydrolase of bacterial or fungal origin is used on an industrial scale to catalyze the hydrolytic removal of the side chain of penicillin to give the nucleus 6-amino penicillanic acid (6-APA).
  • This nucleus is the starting material for the synthesis of broad spectrum penicillins (semi-synthetic) which are prepared by acylation of the amino group.
  • a new antibiotic is thienamycin, (U.S. Pat. No. 3,950,357).
  • the teachings of U.S. Pat. No. 3,950,357 are incorporated herein by reference.
  • N-acyl derivatives of thienamycin are unexpectedly cleaved by penicillin amidohydrolase.
  • the present invention provides a new process for conversion of N-acyl-thienamycins to thienamycin.
  • N-acylthienamycin having the following structure: ##STR1## wherein R 1 and R 2 are independently selected from the group consisting of hydrogen (R 1 and R 2 are not both hydrogen) or an acyl group is contacted in an aqueous medium with enzymes which are capable of removing the N-acyl moiety in order to form thienamycin.
  • Thienamycin has the structure: ##STR2## Thienamycin is a valuable antibiotic which is active against both gram-positive and gram-negative bacteria.
  • the enzymes utilized to remove the N-acyl moiety are penicillin amidohydrolases.
  • the preferred compounds of this invention are those wherein R 1 is hydrogen and R 2 is acyl.
  • acyl is meant the aliphatic and aromatic carboxylic acids including derivatives and analogs thereof such as thio analogs wherein the carbonyl oxygen is replaced by sulphur, diacyl radicals wherein R 1 and R 2 are joined together; as well as the sulphur and phosphorous acyl analogs such as substituted sulfonyl-, sulfinyl-, and sulfenyl-radicals, and substituted P(III) and P(V) radicals such as the substituted phosphorous-, phosphoric-, phosphonous- and phosphonic radicals, respectively.
  • Such acyl radicals of the present invention are further defined below.
  • the N-acyl derivatives may be prepared by any of the techniques well known in the art if the thienamycin has been isolated from the fermentation broth or solution. If the thienamycin has not been isolated from the fermentation broth, then the method of preparing the N-acyl-thienamycin is by reacting the appropriate acyl compound while the thienamycin is still in the broth or solution. Alternatively, the acyl group can be incorporated biosynthetically following supplementation of the fermentation broth with the parent acid or a derivative thereof. These derivatives, by virtue of their increased solubility in organic solvents and additional physical properties, provide alternate and more efficient routes for recovery of the thienamycin nucleus. Once the derivatized thienamycin is recovered from the broth or solution, it can be treated by the methods described in this invention in order to regenerate the thienamycin.
  • the acyl radical represented by either R 1 or R 2 can, inter alia, be substituted or unsubstituted aliphatic, aromatic or heterocyclic, araliphatic or heterocylylaliphatic carboxylic acid radical, a substituted or unsubstituted carbamyl radical or a carbothioic acid radical.
  • One group of acyl radicals can be represented by the general formula: ##STR3## wherein X is O or S and R" represents a straight or branched chain alkyl or alkoxymethylene group containing from 5-10 carbon atoms, aryloxymethylene, typically comprising 6-10 carbon atoms.
  • Such above-listed groups can be unsubstituted or can be substituted by radicals such as OH, SH, SR (R is loweralkyl or aryl such as phenyl), alkyl or alkoxy groups having 1 to about 6 carbon atoms, halo, such as Cl, Br, F and I, cyano, carboxy, sulfamino, carbamoyl, sulfonyl, azido, amino, substituted amino such as alkylamino including quaternary ammonium wherein the alkyl group comprises 1-6 carbon atoms, haloalkyl such as trifluoromethyl, carboxyalkyl, carbamoylalkyl, N-substituted carbamoylalkyl, wherein the alkyl moiety of the foregoing four radicals comprises 1 to about 6 carbon atoms, amidino, guanidino, N-substituted guanidino, guanidino lower alkyl and the like
  • acyl groups that might be mentioned are those wherein R" is benzyl, phenoxymethylene, p-hydroxybenzyl, n-amyl, n-heptyl, 3- or 4-nitrobenzyl, phenethyl, ⁇ , ⁇ -diphenylethyl, methyldiphenylmethyl, triphenylmethyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl, 2,4,6-trimethoxyphenyl, D-4-N-benzoylamino-4-carboxy-n-butyl, p-aminobenzyl, o-aminobenzyl, m-aminobenzyl, p-dimethylaminobenzyl, 2-ethoxy-1-napthyl, 4-guanidinomethylphenyl, 4-guanidinomethylbenzyl, 4-guanidinobenzyl, 4-guanidinophenyl, 2,6-dimethoxy-4-guanidino
  • the preferred compounds that can be utilized in this invention that fit the above acyl radical description are phenylacetyl, p-hydroxyphenylacetyl, phenylglycyl, 2-thienylacetyl, phenoxyacetyl, N-propoxyacetyl and iso-butoxyacetyl.
  • penicillin amidohydrolases to convert penicillins into 6-aminopenicillanic acid (6-APA) is known in the art.
  • penicillin amidohydrolases to remove the N-acyl side chains of N-acylated thienamycin is surprising.
  • the process of this invention may be conducted by reacting the starting material of the general formula I with the enzyme extract from a cultured broth, the filtrate or fermentation product of the Escherichia coli culture or a powder of the enzyme in an aqueous solution.
  • the enzyme may be immobilized by adsorption or chemical reaction to an insoluble supporting structure such as glass, cellulose or agarose, and used to hydrolyse the N-acylated thienamycin either by contacting it in suspension, or by the percolation of the acylated material through a bed of the immobilized enzyme preparation.
  • an insoluble supporting structure such as glass, cellulose or agarose
  • the enzyme is capable of removing N-acyl moietys which were present or produced in fermentation broths as well as those N-acyl groups introduced during isolation of the antibiotic or made by chemical synthesis techniques.
  • N-acylated thienamycin takes place in the presence of an enzyme of the microorganism of the genus Escherichia coli which is able to remove the acyl moiety to provide the antibiotic thienamycin.
  • the amidohydrolase enzyme For the production of the amidohydrolase enzyme by cultivation of the above-mentioned microorganism, there may be used various culture media commonly employed for the cultivation of a microorganism. More specifically, glucose, sucrose, glycerol, starch, oils used for cultivation and the like as a carbon source and peptone, buillion, corn steep liquor, yeast extract, meat extract, fish meal, defatted soybean, wheat embryo and the like as a nitrogen source may be employed. If required, other additives may be employed in combination with the above. It is an advantage but not a necessity to include phenylacetic acid or its salts or derivatives in fermentation media.
  • Escherichia coli is usually shaken or agitated under aeration.
  • Cultivation temperature may range from about 23°-27° C.
  • Cultivation period is usually 20-28 hours.
  • the amidohydrolase contained in the cultured broth or its extract may be utilized in the present process without any further purification.
  • the amidohydrolase enzyme may be precipitated with appropriate solvents, salted out or dialyzed or otherwise purified. It may be used free in solution or immobilized on an appropriate surface.
  • a method utilized in the present invention is that of utilizing the whole cell amidohydrolase preparation. By this method, after cultivation, the culture is centrifuged to obtain the whole cells for subsequent reaction with the derivatized thienamycin.
  • reaction mixtures are incubated 18 hours at 23° C.
  • the assay plates are prepared as follows: An overnight growth of the assay organism, Staphylococcus aureus ATCC 6538P, in nutrient broth plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract to a suspension having 60% transmittance at a wavelength of 660 nm. This suspension is added to Difco nutrient agar supplemented with 2.0 g./l. Difco yeast extract at 47° C. to 48° C., to make a composition containing 33.2 ml. of the suspension per liter of agar. Forty ml. of this suspension is poured into 22.5 cm. ⁇ 22.5 cm. petri plates, and these plates are chilled and held at 4° C. until used (5 days maximum).
  • the TLC plate is removed and the assay plate incubated overnight at 37° C.
  • the additional bioactive spots present at R f 0.39 and R f 0.45 in the enzyme-treated reaction mixtures containing phenylacetyl thienamycin and N-(O-formyl)-1-mandeloyl thienamycin are due to the thienamycin produced by amdohydrolase enzyme reaction.
  • a control containing buffer and enzyme alone produces no bioactive spots.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US05/825,883 1977-08-19 1977-08-19 Enzymatic cleavage of N-acyl-thienamycins Expired - Lifetime US4162193A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US05/825,883 US4162193A (en) 1977-08-19 1977-08-19 Enzymatic cleavage of N-acyl-thienamycins
IT50747/78A IT1106626B (it) 1977-08-19 1978-08-16 Scissione enzimatica di n acil tienamicine
PT68428A PT68428A (en) 1977-08-19 1978-08-16 Process for the preparation of thienamycin by enzymatic cleavage of n-acyl-thienamycins
DE7878100699T DE2861737D1 (en) 1977-08-19 1978-08-18 Enzymatic cleavage of n-acyl-thienamycins
EP78100699A EP0000931B1 (en) 1977-08-19 1978-08-18 Enzymatic cleavage of n-acyl-thienamycins
DK365478A DK365478A (da) 1977-08-19 1978-08-18 Fremgangsmaade til enzymatisk spaltning af n-acyl-thienamycindner
ES472701A ES472701A1 (es) 1977-08-19 1978-08-18 Un metodo para la preparacion de tienamicina
IE1674/78A IE47315B1 (en) 1977-08-19 1978-08-18 Enzymatic cleavage of n-acyl-thienamycins
JP10046478A JPS5446890A (en) 1977-08-19 1978-08-19 Enzymatic split of nnacyllthienamycine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/825,883 US4162193A (en) 1977-08-19 1977-08-19 Enzymatic cleavage of N-acyl-thienamycins

Publications (1)

Publication Number Publication Date
US4162193A true US4162193A (en) 1979-07-24

Family

ID=25245138

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/825,883 Expired - Lifetime US4162193A (en) 1977-08-19 1977-08-19 Enzymatic cleavage of N-acyl-thienamycins

Country Status (9)

Country Link
US (1) US4162193A (enrdf_load_stackoverflow)
EP (1) EP0000931B1 (enrdf_load_stackoverflow)
JP (1) JPS5446890A (enrdf_load_stackoverflow)
DE (1) DE2861737D1 (enrdf_load_stackoverflow)
DK (1) DK365478A (enrdf_load_stackoverflow)
ES (1) ES472701A1 (enrdf_load_stackoverflow)
IE (1) IE47315B1 (enrdf_load_stackoverflow)
IT (1) IT1106626B (enrdf_load_stackoverflow)
PT (1) PT68428A (enrdf_load_stackoverflow)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02135843U (enrdf_load_stackoverflow) * 1988-11-08 1990-11-13

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB939708A (en) 1961-06-01 1963-10-16 Beecham Res Lab Production of ª -hydroxybenzylpenicillin
US3304236A (en) * 1963-11-19 1967-02-14 Ciba Geigy Corp Process for the manufacture of desacetyl-7-amino-cephalosporanic acid
US3912589A (en) * 1973-05-14 1975-10-14 Glaxo Lab Ltd Preparation of cephalosporin compounds
US3945888A (en) * 1972-12-06 1976-03-23 Takeda Chemical Industries, Ltd. Method for the production of cephalosporins
US3950357A (en) * 1974-11-25 1976-04-13 Merck & Co., Inc. Antibiotics
US3975235A (en) * 1974-03-11 1976-08-17 Meiji Seika Kaisha, Ltd. Process for the production of cephamycin type antibiotic substances

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1111778B (de) * 1959-04-18 1961-07-27 Bayer Ag Verfahren zur Herstellung von 6-Aminopenicillansaeure
DK497476A (da) * 1975-11-24 1977-05-25 Merck & Co Inc Fremgangsmade til fremstilling af et antibiotisk stof
NL7800958A (nl) * 1977-02-11 1978-08-15 Merck & Co Inc Antibioticum desacetyl-dihydro 890 a9, werkwijze ter bereiding daarvan en farmaceutisch preparaat dat dit antibioticum bevat.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB939708A (en) 1961-06-01 1963-10-16 Beecham Res Lab Production of ª -hydroxybenzylpenicillin
US3304236A (en) * 1963-11-19 1967-02-14 Ciba Geigy Corp Process for the manufacture of desacetyl-7-amino-cephalosporanic acid
US3945888A (en) * 1972-12-06 1976-03-23 Takeda Chemical Industries, Ltd. Method for the production of cephalosporins
US3912589A (en) * 1973-05-14 1975-10-14 Glaxo Lab Ltd Preparation of cephalosporin compounds
US3975235A (en) * 1974-03-11 1976-08-17 Meiji Seika Kaisha, Ltd. Process for the production of cephamycin type antibiotic substances
US3950357A (en) * 1974-11-25 1976-04-13 Merck & Co., Inc. Antibiotics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Advances in Applied Microbiology, vol. 17, pp. 311-319 (1974). *
Journal of Biochemistry, vol. 115, pp. 733-739 (1969). *

Also Published As

Publication number Publication date
IT1106626B (it) 1985-11-11
DK365478A (da) 1979-02-20
DE2861737D1 (en) 1982-05-27
EP0000931A1 (en) 1979-03-07
ES472701A1 (es) 1979-02-16
JPS5446890A (en) 1979-04-13
IE47315B1 (en) 1984-02-22
EP0000931B1 (en) 1982-04-14
IT7850747A0 (it) 1978-08-16
PT68428A (en) 1978-09-01
IE781674L (en) 1979-02-19
JPS6210639B2 (enrdf_load_stackoverflow) 1987-03-07

Similar Documents

Publication Publication Date Title
US4526783A (en) Antibiotic from S. clavuligerus
US3239394A (en) Process for producing 7-amino-cephalosporanic acid
Shimizu et al. Search for microorganisms producing cephalosporin acylase and enzymatic synthesis of cephalosporins
Huber et al. Preparative methods for 7-aminocephalosporanic acid and 6-aminopenicillanic acid
US4162193A (en) Enzymatic cleavage of N-acyl-thienamycins
US6156534A (en) Synthesis of β-lactam antibacterials using soluble side chain esters and enzyme acylase
EP0001567B1 (en) Thienamycin related antibiotics ps-6 and ps-7, process for their production and compositions containing them
GB2058776A (en) Esters and their use in the synthesis of -lactam antibacterial compounds
EP0000932B1 (en) Production of n-acyl-thienamycins
US4141790A (en) Process for the preparation of 7-amino-cephem compounds using mold fungi
EP0052974B1 (en) Improvements in enzymatic deesterification
US4073687A (en) Enzymatic acylation to afford β-lactam antibiotics
GORDON et al. Cephamycin antibiotics
US4587333A (en) Cephalosporins and their production
US3905868A (en) Enzymatic deacylation of benzyl- and phenoxymethylpenicillin tetrazoles
US4656288A (en) Antibiotics, their production and use
EP0019409B1 (en) Process for the preparation of penicillin derivatives and compounds so obtained
US3522250A (en) Derivatives of 7-aminocephalosporanic acid
WO1992017600A1 (en) Enzymatic process for the production of cefonicid
CA1238594A (en) Antibiotics, tan-558, their production and use
US4205068A (en) β-Lactamase inhibitor EM4615
Serizawa et al. Enzymatic conversion of cephamycin C by D-amino acid oxidase from Trigonopsis variabilis
US4448723A (en) Antibiotics PA-41746-B and C
US3616223A (en) Penicillin intermediate
US3088880A (en) 6-aminopenicillanic acid amide production